To assess the prognostic value of an abnormal postexercise response in systolic blood pressure (SBP), treadmill exercise testing was performed in 217 survivors of acute myocardial infarction at an average of 9.3 weeks after infarction. During the mean follow-up period of 4 years, cardiac events were noted in 34 patients (16%), including cardiac death in 13 (6%), nonfatal reinfarction in 12 (6%), and coronary artery bypass graft surgery in nine (4%). An abnormal postexercise SBP response was defined as the ratio of SBP at 3 minutes of recovery to peak exercise SBP of 0.9 or more, on the basis of the cutoff point with the highest sensitivity and specificity to predict cardiac events. An abnormal postexercise SBP response occurred in 90 patients (42%). Patients with an abnormal postexercise SBP response had more exercise-induced myocardial ischemia. more left ventricular impairment, and more extensive coronary artery lesions than those without. Cox proportional hazards model demonstrated that the abnormal postexercise SBP response was ranked first in ability to predict cardiac death (p = 0.025, relative risk 15.41). Bypass surgery was associated with an abnormal postexercise SBP ratio (p less than 0.05). Nonfatal reinfarction could not be predicted by any clinical or exercise variables. In conclusion, an abnormal postexercise SBP response could be useful for predicting cardiac death and the need for bypass surgery after myocardial infarction. This response is probably the result of myocardial ischemia and left ventricular impairment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0002-8703(05)80015-8 | DOI Listing |
Cardiol Rev
October 2024
Department of Cardiology, Royal Devon University Healthcare National Health Service Foundation Trust, Exeter, United Kingdom.
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by structural and functional abnormalities. Current management strategies, such as medications and septal reduction therapies, have significant limitations and risks. Recently, cardiac myosin inhibitors (CMIs) like mavacamten and aficamten have shown promise as noninvasive treatment options.
View Article and Find Full Text PDFSleep Med Rev
November 2024
Department of Medicine and Neurology, Hi-Tech Medical College and Hospital, Utkal University, Bhubaneswar, 752101, Odisha, India. Electronic address:
J Sci Med Sport
September 2024
Asthma, Allergy and Clinical Immunology Service, Alfred Health, Australia; Central Clinical School, Monash University, Australia.
Cureus
August 2024
Department of Occupational Therapy, Faculty of Rehabilitation, Niigata University of Health and Welfare, Niigata, JPN.
Understanding the risk factors for cognitive impairment in interstitial lung disease (ILD) can help guide disease management tailored to cognitive function. However, no review articles or randomized controlled trial articles have been found for cognitive impairment in ILD. This scoping review aimed to systematically map studies on factor-related cognitive impairment in ILD and organize current knowledge.
View Article and Find Full Text PDFAm J Cardiol
December 2024
Hypertrophic Cardiomyopathy Center, Cleveland Clinic, Cleveland, Ohio. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!